Resistance to inhibitors of the human immunodeficiency virus type 1 integration
AUTOR(ES)
Hazuda, Daria J
FONTE
Brazilian Journal of Infectious Diseases
DATA DE PUBLICAÇÃO
2010-10
RESUMO
This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 infection
Documentos Relacionados
- Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors
- Monitoring Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors by Pyrosequencing
- Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors
- Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.
- Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.